Morbidity and Mortality Weekly Report (MMWR)

This report describes CDC findings from the Autism and Developmental Disabilities Monitoring Network for children aged 8 years in 2020.

This report describes CDC findings from the Autism and Developmental Disabilities Monitoring Network for children aged 4 years in 2020.

This report describes the percentage of adults who experienced serious psychological distress during the past 30 days by family income.

This report describes an increase in TB in the United States during 2022 and ongoing disparities in TB incidence among certain race and ethnicity groups.

This report describes an evaluation of treatment adherence to video direct observed therapy for tuberculosis treatment.

This report describes reported tuberculosis cases among people who were incarcerated in Washington state.

This report describes disruptions to continuity of care for people in Dharavi with drug-resistant tuberculosis.

This report describes the worldwide progress of eliminating HIV as a global public health threat through the use of antiretroviral therapy.

This report describes age-adjusted drug overdose death rates by state.

This report is a correction and republication to an MMWR released December 16, 2022, on early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19–associated emergency department or urgent care visits among immunocompetent adults.

This report describes an increase in babesiosis cases in the U.S. during 2011–2019.

This report describes the identification of dengue virus in Maricopa County, Arizona.

This report describes the prevalence of previous dengue virus infection among children and adolescents in the U.S. Virgin Islands.

This report describes an increase in primary COVID-19 vaccination series completion among Seattle Public School students through a COVID-19 vaccination program.

This report describes the proportion of nonfatal injury-related emergency department visits among incarcerated adults compared to nonincarcerated adults.

This report describes the percentage of adults aged ≥45 years who reported subjective cognitive decline.

This report describes the percentage of cigarette smokers, former cigarette smokers and non-cigarette smokers among current adult e-cigarette users.

Erratum for MMWR Vo. 72, No.2

This report describes surveillance of a resurgence of invasive group A Streptococcus in children and adolescents in Colorado and Minnesota.

This report describes the identification of HIV cluster among Hispanic or Latino gay, bisexual, and other men who have sex with men in Atlanta.

This report describes the percentage of adults aged ≥45 years who reported subjective cognitive decline.

Erratum for MMWR Vo. 72, No. 07

This report describes efforts to reduce female-to-male transmission of HIV through CDC supported voluntary male circumcision programs.

This report describes the percentage of adults who used telemedicine in the past 23 months.

This report describes a survey of people accessing homeless services or staying in encampments who may have been previously infected with undetected mpox.

This report describes detection of Cronobacter sakazakii in two infants linked to powdered infant formula and breast pump equipment.

This report describes acute kidney injury linked to imported pediatric medications among children in Gambia.

This report describes interim clinical treatments for severe mpox developed following the evaluation of treatment data, cases, input from clinicians, and more.

This report describes the percentage of U.S. adults 18 years and older who experienced serious psychological distress in the past 30 days.

This report describes characteristics of the XBB 1.5 Variant in New York City during November–December 2022.

This report describes surveillance of aircraft wastewater for early detection of potential COVID-19 variants.

This report describes postarrival COVID-19 testing among volunteering international air travelers.

This report describes 54% effectiveness for the 2023-23 influenza vaccine for preventing medically attended influenza A infection in people older than 65 years.

This report describes the percentage of women aged 50–74 years who had a mammogram within the past two years.

This report describes COVID-19 bivalent booster vaccination coverage and intent to receive booster vaccination among adolescents and adults.

This report describes low COVID-19 vaccination coverage with one or more dose among younger children compared to older children.

This report describes infrequent intake of fruits and vegetables among young children in the United States.

This report describes up to 4 months of protection against COVID-19 among children aged 3–5 and 3–4 year who received monovalent primary series vaccinations.

This report describes high typhoid incidence in South-East Asian, Easter Mediterranean, and African regions.

This report describes the percentage of adult aged ≥45 years who use a hearing aid.

This report describes an increase in suicide rates during 2021 in the United States.

This report describes higher protection against COVID-19 infection and death among people who received an updated booster than people who received a monovalent booster.

This report describes vaccine-specific changes in the 2023 immunization schedule for adults aged ≥19 years.

This report describes changes to the 2023 immunization schedule for children and adolescents aged ≤18 years.

This report describes how race, ethnicity, and socioeconomic factors affected hemodialysis-associated S. aureus bloodstream infections.

This report describes how the median completed COVID-19 vaccinations series among older adults in 2022 was 76%, which is below the WHO goal, especially in middle- and low-income countries.

This report describes how one third of people of all ages used telemedicine with in the previous 12 months during 2021.

This report describes measures that people who are immunocompromised can take to prevent and treat COVID-19.

This report describes how continued monitoring of S-gene target failure and S-gene target presence patterns will likely serve as a useful complement to genomic surveillance of SARS-CoV-2 lineages.

This report describes how a bivalent mRNA booster dose provided additional protection against symptomatic XBB/XBB.1.5 infection for at least the first 3 months after vaccination in persons who had previously received 2–4 monovalent vaccine doses.